SFDA Chief Highlights Product Safety And Availability In Pharma Industry Meeting

Dr. Hisham bin Saad Aljadhey, CEO of the Saudi Food and Drug Authority (SFDA), met with CEOs from local and international pharmaceutical companies at the SFDA headquarters in Riyadh. The discussions aimed to bolster cooperation and align with Saudi Vision 2030, focusing on developing national industries and advancing the SFDA's fourth strategic plan.

The SFDA's fourth strategic plan prioritises product safety and aims to enhance product availability. Dr. Aljadhey stressed the importance of these meetings in addressing challenges and supporting companies to meet requirements for ensuring medicine availability, safety, and effectiveness. He reiterated that the SFDA is always open to investors' feedback, opinions, inquiries, and comments.

Company representatives praised the SFDA's high level of transparency, which fosters a collaborative environment between companies and the regulatory body in Saudi Arabia. They acknowledged the significant development the sector has experienced recently.

The SFDA aims to empower investors in the pharmaceutical sector through its fourth strategic plan, positioning Saudi Arabia as a global leader in this field. Dr. Aljadhey conducts periodic meetings with food, pharmaceutical, and medical device companies to promote communication and transparency across these sectors.

Dr. Aljadhey highlighted that the authority is committed to providing comprehensive support to preserve public health by ensuring the safety of medicines available in the Saudi market. He emphasized that these meetings are crucial for addressing challenges faced by companies.

"The SFDA is always open to investors," said Dr. Aljadhey. "We welcome their feedback, opinions, inquiries, and comments."

Through continuous dialogue with industry leaders, the SFDA seeks to ensure that companies can meet necessary requirements for guaranteeing medicine safety and effectiveness.

The discussions also explored strategies to align with Saudi Vision 2030 objectives, particularly in developing national industries. This alignment is essential for advancing the SFDA's goals and supporting economic growth within the Kingdom.

The commitment of the SFDA to maintaining high standards of transparency was commended by company representatives. This approach has significantly contributed to fostering a collaborative environment between businesses and regulatory authorities.

The meeting underscored the importance of collaboration between regulatory bodies and industry players in achieving shared goals. By working together, they aim to enhance product safety and availability while supporting national industry development.

The ongoing efforts by Dr. Aljadhey and his team reflect a dedication to fostering an environment where public health is safeguarded through stringent regulatory practices.

With inputs from SPA